Vyriad, a gene therapy company based in Rochester, has raised $85 million to support its new VV-169 cancer treatment which ...

Scientists have found a way to fine-tune a central fat-control pathway in the liver, reducing harmful blood triglycerides ...

In this week's "It's Debatable" segment, Rick Rosen and Charles Moster debate on the question: Should ethical/legal restrictions on human testing be lifted to expedite the development of new ...

Following successful small-animal trials that confirmed bioequivalence, BioNxt is now taking the final preclinical step to prepare its sublingual Cladribine formulation for human testing. The upcoming ...